SIRP alpha

SIRP alpha 분자 정보

영어 이름Signal-regulatory protein alpha시판 약물 수2
임상 약물 수19표적 별명SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
최고 연구 개발 단계Approved
영어 이름Signal-regulatory protein alpha
표적 별명SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
시판 약물 수2
임상 약물 수19
최고 연구 개발 단계Approved

SIRP alpha분자 배경

Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

SIRP alpha분자 별명

SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
IpsoprubartELA-026Phase 3 ClinicalElectra Therapeutics IncLymphohistiocytosis, Hemophagocytic; Neoplasms
상세
LM-101LM-101Phase 2 ClinicalLaNova Medicines LtdHematologic Neoplasms; Leukemia; Neoplasms; Solid tumours
상세
HX-044HX044; HX-044Phase 2 ClinicalHanx Biopharmaceuticals Pty LtdLymphoma; Solid tumours
상세
BRB-002BRB-002Phase 2 ClinicalBitterroot Bio IncAtherosclerosis; Cardiovascular Diseases; Vasculitis
상세
BI-770371BI-770371Phase 2 ClinicalOse ImmunotherapeuticsCarcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck
상세
IBC-0966IBC-0966Phase 2 ClinicalNeoplasms
상세
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty LtdBile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
상세
BI-765063OSE-172; BI-765063; Effi-DEMPhase 1 ClinicalEffimuneCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
상세
ADU-1805ADU-1805Phase 1 ClinicalAduro Biotech IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours
상세
Q-1801Q-1801; Q 1801Phase 1 ClinicalQure Biotechnology (Shanghai) Co LtdSolid tumours
상세
Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo)DS-1103aPhase 1 ClinicalDaiichi Sankyo Co LtdBreast Neoplasms; Solid tumours
상세
JY-47JY47; JY-47Phase 1 ClinicalHangzhou Jiuyuan Gene Biomedical Co LtdLiver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours
상세
BYON-4228BYON-4228Phase 1 ClinicalSanquin Blood Supply FoundationLymphoma; Solid tumours
상세
BSI-082BSI-082Phase 1 ClinicalBiosion IncHematologic Neoplasms; Neoplasm Metastasis; Solid tumours
상세
BR-105BR-105; BR105Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co LtdLymphoma, Large B-Cell, Diffuse; Neoplasms
상세
[89Zr]Zr- BI-765063(Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim CorpCarcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck
상세
TQB-2928TQB-2928Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours
상세
BI-765080Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
상세
ES-004ES-004; ES 004-N4; ES 004-B4Phase 1 ClinicalElpiscience (Shanghai) Biopharma LtdNeoplasms; Solid tumours
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Relugolix/Estradiol/Norethindrone AcetateE2/NETAApprovedMyovant SciencesMYFEMBREE, RYEQOUnited StatesMenorrhagia; LeiomyomaSumitomo Pharma America Inc, Myovant Sciences2021-05-26Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms
상세
Elagolix/estradiol/norethindrone acetateApprovedAbbvie IncOriahnnUnited StatesMenorrhagiaAbbvie Inc2020-05-29Menorrhagia
상세

제품 리뷰

  • R***n2024-06-03
    0사람들이 좋아합니다
    I recently used the PE-Labeled Human SIRP alpha / CD172a Protein, Fc Tag for detecting the expression of CD47 in Jurkat T-cells and primary T-cells, and I am very pleased with the results. The SIRP alpha reagent effectively binds to CD47 overexpressed in both Jurkat and primary T-cells. This experiment was conducted to demonstrate the overexpression of CD47 in T-cells, using the anti-CD47 antibody (clone: CC2C6) to confirm the expression. Additionally, it was crucial to show that our CD47 can bind to its natural ligand, SIRP alpha. The reagent performed excellently in this regard, providing clear and reliable results. I've attached an image showing the data with a CD47 KO Jurkat cell line, further validating the specificity and effectiveness of this reagent. Overall, I highly recommend this product for CD47 detection and binding studies.
  • J***r2022-08-18
    0사람들이 좋아합니다
    I used this SIRPa-PE Fc tag for a FACS assay using the recommended SOP provided by Acro and our rep Nik Kamachi. Nik was very helpful in providing insight on the capabilities of Acro to provide custom labeled SIRPa Fc tags to meet our needs for small molecule screening assays that are FACS and IF-based. The human SIRPa-PE Fc tag was very easy to use and gave a strong signal with both flow cytometry and imaging
  • M***g2022-05-07
    1사람들이 좋아합니다
    We purchased the SIRP-alpha-Fc protein for CD47 competition studies via BLI. The protein was delivered quickly and easy to resuspend following the instructions in the COA. We observed strong binding for this protein to CD47 and minimal background binding to the sensors. We were also able to demonstrate competition with commercially available antibodies. Overall, this product specifically binds CD47 and worked well in BLI based competition assays.
더 불러오기
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 제품 리뷰
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호